Abstract Details

Title Psychiatric and Cognitive Profile in the Post-Acute Stage of Anti-NMDA Receptor Encephalitis: A Comparative Analysis with Patients with Schizophrenia.

Topic Autoimmune Neurology

Presentation(s) Autoimmune Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 036

Objective To report the psychiatric and cognitive profiles of patients in the post-acute stage of anti-NMDAR encephalitis (aNMDARe) and compare them with patients with schizophrenia (SCHZ) and healthy controls (HC).

Background aNMDARe encephalitis is an autoimmune disorder that causes severe neuropsychiatric and cognitive dysfunction. The similarity of some symptoms with schizophrenia has not been thoroughly investigated.

Design/Methods The study included 25 aNMDARe patients (median age: 27.3; median months from onset: 3.9), 25 SCHZ patients (median age: 19.8; median months from onset: 38.4) and 25 HC (median age: 23.1). All cases underwent a semi-structured psychiatric interview, and were assessed for mania, depression and psychotic symptoms, and overall functioning. A neuropsychological assessment was performed with tests evaluating intelligence, verbal and visual memory, auditory and visuospatial working memory, processing speed, sustained attention, and executive functions.

Results Compared with HC, aNMDARe patients had more attention deficit disorder symptoms (p=0.037), mania (p<0.001) and depressive symptoms (p<0.001), positive (p=0.028), negative (p<0.001) and general (p<0.001) psychotic symptoms, and lower overall functioning (p<0.001). No differences were identified between aNMDARe and SCHZ patients except for less positive psychotic symptoms in aNMDARe cases (p=0.007). Regarding the cognitive profile, aNMDARe patients had worse performance than HC in all cognitive domains (intelligence p<0.001; auditory working memory p=0.002; visuospatial working memory p=0.029; processing speed p=0.001; verbal fluency p<0.001; immediate verbal memory p=0.009; long-term verbal memory p=0.002; immediate visual memory p=0.021; executive functions p<0.001; sustained attention p=0.012) except for long-term visual memory (p=0.073). Compared to SCHZ, aNMDARe patients did not show significant differences in any cognitive area, except for better immediate verbal memory (p=0.035).

Conclusions The pattern of neuropsychiatric and cognitive deficits is highly similar in aNMDARe and SCHZ patients. The findings are important in order to clinically and neuropsychologically characterize these patients whose disease mechanisms (autoimmune in aNMDARe vs non-autoimmune in SCHZ) entail different treatments.

Authors/Disclosures
PRESENTER	No disclosure on file
Mar Guasp, MD (Hospital Clínic Barcelona - IDIBAPS)	Dr. Guasp has nothing to disclose.
	No disclosure on file
Eugenia Martinez-Hernandez, MD (Hospital Clinic Barcelona)	Dr. Martinez-Hernandez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Martinez-Hernandez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Martinez-Hernandez has received research support from Instituto de Salud Carlos III. The institution of Dr. Martinez-Hernandez has received research support from Fundacio La Caixa. Dr. Martinez-Hernandez has received personal compensation in the range of $500-$4,999 for serving as a support for attending meetings and speaker honoraria with UCB. Dr. Martinez-Hernandez has received personal compensation in the range of $500-$4,999 for serving as a speaker honoraria and attending meetings with Alexion. Dr. Martinez-Hernandez has received personal compensation in the range of $500-$4,999 for serving as a support for attending meetings with CSL Behring.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Josep O. Dalmau, MD, PhD, FAAN	Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas Research Institute of America. Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Research & Development . Dr. Dalmau has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ��ɫ��. An immediate family member of Dr. Dalmau has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Dalmau has received research support from Sage Therapeutics. The institution of Dr. Dalmau has received research support from Edmond J.Safra Foundation . The institution of Dr. Dalmau has received research support from La Caixa Foundation. The institution of Dr. Dalmau has received research support from Spanish Ministry of Health (ISCIII). The institution of Dr. Dalmau has received research support from Euroimmun, Inc. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care.
	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��